These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8382722)

  • 21. Immunogenicity of purified glycoprotein gB of herpes simplex virus.
    Kino Y; Eto T; Nishiyama K; Ohtomo N; Mori R
    Arch Virol; 1986; 89(1-4):69-80. PubMed ID: 3013134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D.
    Berman PW; Gregory T; Crase D; Lasky LA
    Science; 1985 Mar; 227(4693):1490-2. PubMed ID: 2983428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of experimental animals with reconstituted glycoprotein mixtures of herpes simplex virus 1 and 2: protection against challenge with virulent virus.
    Meignier B; Jourdier TM; Norrild B; Pereira L; Roizman B
    J Infect Dis; 1987 May; 155(5):921-30. PubMed ID: 3031174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
    Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
    Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous Herpes simplex virus: implications for a herpes virus vaccine.
    Scriba M
    Med Microbiol Immunol; 1978 Nov; 166(1-4):63-9. PubMed ID: 214688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy.
    Stanberry LR; Harrison CJ; Bernstein DI; Burke RL; Shukla R; Ott G; Myers MG
    Antiviral Res; 1989; 11(4):203-14. PubMed ID: 2545166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunity induced by DNA immunization with herpes simplex virus type 2 glycoproteins B and C.
    Mester JC; Twomey TA; Tepe ET; Bernstein DI
    Vaccine; 1999 Dec; 18(9-10):875-83. PubMed ID: 10580201
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
    Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
    J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of recombinant glycoprotein D subunit vaccines on the development of primary, recurrent, and latent genital infections with herpes simplex virus type 2 in guinea pigs.
    Berman PW; Vogt PE; Gregory T; Lasky LA; Kern ER
    J Infect Dis; 1988 May; 157(5):897-902. PubMed ID: 2834467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection.
    Harrison CJ; Jenski L; Voychehovski T; Bernstein DI
    Antiviral Res; 1988 Dec; 10(4-5):209-23. PubMed ID: 2465735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute and latent herpes simplex virus neurological disease in mice immunized with purified virus-specific glycoproteins gB or gD.
    Dix RD; Mills J
    J Med Virol; 1985 Sep; 17(1):9-18. PubMed ID: 2995573
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.
    Burke RL
    Rev Infect Dis; 1991; 13 Suppl 11():S906-11. PubMed ID: 1664126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-mediated immunologic responses and recurrent genital herpes in the guinea pig. Effects of glycoprotein immunotherapy.
    Bernstein DI; Harrison CJ; Jenski LJ; Myers MG; Stanberry LR
    J Immunol; 1991 May; 146(10):3571-7. PubMed ID: 1851194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Herpes simplex virus DNA vaccine efficacy: effect of glycoprotein D plasmid constructs.
    Strasser JE; Arnold RL; Pachuk C; Higgins TJ; Bernstein DI
    J Infect Dis; 2000 Nov; 182(5):1304-10. PubMed ID: 11023454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Detection of asymptomatic initial herpes simplex virus (HSV) infections in animals immunized with subunit HSV glycoprotein vaccines.
    Bernstein DI; Ashley RL; Stanberry LR; Myers MG
    J Clin Microbiol; 1990 Jan; 28(1):11-5. PubMed ID: 2153698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected.
    Bourne N; Milligan GN; Stanberry LR; Stegall R; Pyles RB
    J Infect Dis; 2005 Dec; 192(12):2117-23. PubMed ID: 16288376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Herpes simplex virus glycoprotein treatment of recurrent genital herpes.
    Stanberry LR; Burke R; Myers MG
    J Infect Dis; 1988 Jan; 157(1):156-63. PubMed ID: 2826603
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes simplex virus type 1 envelope subunit vaccine not only protects against lethal virus challenge, but also may restrict latency and virus reactivation.
    Rajcáni J; Sabó A; Mucha V; Kostál M; Compel P
    Acta Virol; 1995 Feb; 39(1):37-49. PubMed ID: 7572468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Successful application of prime and pull strategy for a therapeutic HSV vaccine.
    Bernstein DI; Cardin RD; Bravo FJ; Awasthi S; Lu P; Pullum DA; Dixon DA; Iwasaki A; Friedman HM
    NPJ Vaccines; 2019; 4():33. PubMed ID: 31396405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.